Abstract: Conjugates of 2,3-dihydroxynaphthalene and its derivatives with enzyme cleavable groups are chromogenic substrates that form colored compounds when complexed with metal ions, e.g. iron ions, on cleavage by enzymes, and are useful in microbial detection and identification. The cleavage products form purple or red-brown colored complexes, that can easily be observed by the naked eye. Microbes can be grown in the presence of the substrates and the metal salts that provide the metal ion for complexing with the 2,3-dihydroxynaphthalene product. Substituents in the naphthalene ring may affect the solubility of the substrates and also the diffusibility and color of the metal complexes. Some of the substrates yield soluble complexes on cleavage and are of particular value in liquid growth media. Other substrates produce less soluble complexes that are more suitable for use in solid agar media. Methods of synthesizing the substrates are described.

Abstract: Chromogenic substrates for ?-D-glucuronidase activity comprising monoglucuronides of some 1,2-dihydroxyaromatic derivatives. When cleaved these form soluble colored conjugates with multivalent metal ions such as iron ions. The substrates may be used in conjunction with chromogenic substrates for other enzymes in microbial detection and identification especially involving liquid media. Microbes can be grown in the presence of the substrates and the compounds providing the metal ion. The substrates are particularly useful for detecting ?-D-glucuronidase-positive E. coli. Synthetic methods for making the compounds are described.

Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.

Abstract: Methods for inhibiting cancer cell proliferation and killing cancer cells are disclosed. Such methods comprise treating cancer cells with an indole compound having the structure of formula (I): wherein R is defined herein.

Abstract: The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.

Abstract: Process are provided which are effective for controlling medium conductivity during fermentation of a CO-containing gaseous substrate while providing an STY of about 10 g ethanol/(L·day) or more. The process includes balancing medium conductivity, specific carbon uptake or cell density levels.

Abstract: The present invention relates to a method for preparing a hydrogel, including the steps of: preparing an enzyme-immobilized support; making contacting with a polymer having a phenol or aniline functional group at a side change and the support in the presence of hydrogen peroxide to cross-link the same; and obtaining a hydrogel by separating the enzyme-immobilized support. According to the present invention, a hydrogel is formed by cross-linking a polymer having a phenol or aniline functional group at a side chain through an enzyme-immobilized support, and thus a hydrogel containing no enzymes is obtained. Therefore, the biomedical application range of a hydrogel can be expanded since it is possible to overcome an in vivo safety problem such as immune reaction caused by an enzyme.

Abstract: Compositions and methods are disclosed for substantially liquid, gel, suspension, slurry, semisolid and/or colloid storage of biological samples following admixture with the herein disclosed storage composition, permitting substantial recovery of biological activity following storage without refrigeration. In certain embodiments, unfractionated saliva samples may be stored without refrigeration for weeks, months or years in a form that permits recovery of intact DNA following the storage period.

Abstract: This invention relates to substrates and methods for the visualization of intracellular organelles, such as the lysosome, peroxiosome, nucleus, Endoplasmic Reticulum and Golgi Apparatus, based upon organelle enzyme activity. Such compounds represent a novel combination of chemically distinct enzyme substrates with targeting and detection substrates which are activated by enzyme activity inside target organelles to produce a detectable signal. The organelle targeted enzyme substrates of this invention are designed to provide high fluorescence at lower pH values found in some organelles and can be used for monitoring enzyme activity inside cells at very low concentrations.

Abstract: The present invention relates to gel compositions comprising at least one entrapped active component.

Abstract: A method of detecting a ligase expressing micro-organism in a sample comprises steps of treating the sample under conditions that inhibit the activity of ATP-dependent ligase from mammalian cells but which do not inhibit the activity of the microbial ligases, contacting the sample or a portion of the sample with a nucleic acid molecule which acts as a substrate for ligase activity in the sample, incubating the thus contacted sample under conditions suitable for ligase activity; and specifically determining the presence and/or the amount of a ligated nucleic acid molecule resulting from the action of the ligase on the substrate nucleic acid molecule to indicate the presence of the ligase expressing micro-organism. The micro-organism may be a fungus or a bacterium or both. High pH conditions may be employed to inactivate mammalian ligases. Related kits are described.

Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.

Abstract: A process for producing hydroxyalkanoate copolymers, which comprises: (i) pre-treating a sucrose-containing feedstock in an acidic solution; (ii) feeding the pre-treated feedstock into a bioreactor containing polyhydroxyalkanoate producing microbial cells; (iii) cultivating the polyhydroxyalkanoate producing microbial cells to form a cell mass containing the hydroxyalkanoate copolymers; (iv) recovering the hydroxyalkanoate copolymers from the cell mass. The pre-treating step has the main function of hydrolyzing sucrose into glucose and fructose, which in turn are converted into 4-ketovaleric acid to give a mixture of mono-saccharides and organic precursors for microbial synthesis of hydroxyalkanoate copolymers, and particularly of PHBVV ter-polymers. Complex and expensive purification processes of the substrates obtained from the pre-treating step are not needed. The solutions can be directly used as the feeding solutions for microbial PHA biosynthesis.

Abstract: Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described.

Abstract: The present invention generally relates to compositions and methods for the handling of processed sperm populations including samples that are freshly collected, those transported as fresh samples, as well as samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the sperm cell. Such trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the sperm's ability to fertilize an egg, grow into a health embryo and produce a healthy offspring.

Abstract: The invention relates to a method for inducing pluripotent stem cells, wherein a mammalian cell is contacted with a compound characterized by a general formula 1 wherein R1 is (CH2)mE, with E being CCH or CN and m being 0, 1, or 2, and R2 is selected from F, CI, Br, OR3 and R3, with R3 being selected from H, (CHyF2-y)n CHXF3-X, with n=0 or 1. The invention further relates to stem cells obtained by the method of the invention, and culture media comprising the compound of the invention.

Abstract: The invention discloses a composition comprising a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion magnesium absorption and/or magnesium retention. The composition preferably further comprises at least one long chain polyunsaturated fatty acid and/or at least one probiotic. This composition is particularly adapted for use in infants notably preterm infants.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses to of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.

Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.